Health Care·Pharmaceuticals·$9.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.54 | N/A | -71.68% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.54 | N/A | -71.68% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding the current market conditions. They emphasized the importance of their ongoing research efforts.
Management did not provide specific guidance for future quarters.
The company is focusing on its ongoing clinical trials and product development.
Axsome Therapeutics reported a significant miss on EPS, which contributed to a 2.33% decline in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's future performance. Management's focus on clinical trials suggests they are prioritizing long-term growth over short-term results.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
EXPEDITORS INTL WASH Class A
Feb 18, 2025